Reviewed by WANGYATAO·Last reviewed 2026-11-11·Medical disclaimer

In short

Around 70 million people in China live with chronic HBV. The 2022 guideline explains the phases of infection, why cccDNA makes cure difficult, how transmission is blocked, and who should be treated.

What this guide covers: The virus · Why it becomes chronic · Transmission · The phases of chronic infection · Prevention

Chronic hepatitis B is a long-term liver inflammation caused by persistent infection with the hepatitis B virus. Globally some 296 million people are chronically infected and around 820,000 deaths a year are attributed to HBV-related cirrhosis, liver failure and hepatocellular carcinoma. China has made enormous progress — childhood vaccination has cut HBsAg prevalence in young children from around 10 percent to well under 1 percent — but the absolute burden remains large, with an estimated 70 million chronic carriers.

The 2022 Chinese guideline on prevention and treatment of chronic hepatitis B, issued by the Chinese Society of Hepatology and the Chinese Society of Infectious Diseases, updates the 2019 edition.

The virus

HBV is a partially double-stranded DNA virus. The infectious particle — the Dane particle — is about 42 nm across, with a surface envelope carrying HBsAg and a core containing HBcAg, HBeAg, the viral DNA and polymerase. The genome has four open reading frames: S, C, P and X, with the X protein implicated in hepatocarcinogenesis.

Ten genotypes, A through J, are described. China is dominated by genotypes B and C, with C more common in the north and carrying a higher risk of cirrhosis and cancer. Because the viral polymerase lacks proofreading ability, variants arise readily — including precore and basal core promoter mutants that produce HBeAg-negative disease, and polymerase mutants that confer drug resistance.

Why it becomes chronic

After entry, the relaxed circular DNA is converted in the nucleus into covalently closed circular DNA, or cccDNA. cccDNA is the template for viral transcription and it persists. This is the central reason chronic hepatitis B is difficult to cure: treatment suppresses replication, but the nuclear template remains.

Transmission

HBV spreads through blood, from mother to child, and sexually. In China, mother-to-child transmission has historically been the dominant route — without intervention, 70 to 90 percent of infants born to HBeAg-positive mothers become infected, compared with 5 to 10 percent for HBeAg-negative mothers. Blood-borne transmission has been greatly reduced by screening and single-use equipment but persists with injecting drug use and unsafe medical practice. Unprotected sex with multiple partners remains a recognised route.

The phases of chronic infection

The guideline describes four phases that can overlap and shift.

Immune tolerance: HBsAg positive, HBeAg positive, very high HBV DNA, normal ALT, minimal histological activity — typical of perinatally acquired infection and lasting for decades.

Immune clearance, or HBeAg-positive chronic hepatitis: ALT rises, HBV DNA falls somewhat, and histology shows moderate to severe inflammation with faster fibrosis progression. HBeAg seroconversion may occur here.

Inactive carrier state: HBeAg negative with anti-HBe positive, low or undetectable DNA, persistently normal ALT, and minimal activity. Risk is lower but not zero.

Reactivation, or HBeAg-negative chronic hepatitis: driven by precore or basal core promoter variants, with fluctuating ALT and DNA and ongoing fibrosis risk.

Prevention

Vaccination is the foundation, and China's infant programme has been the single biggest driver of the fall in prevalence. Preventing mother-to-child transmission combines maternal antiviral therapy in the third trimester where indicated with hepatitis B immunoglobulin and vaccine to the newborn within hours of birth. Standard precautions, screening of blood products and safe injection practice cover the rest.

Treatment principles

Treatment decisions depend on the phase, the level of HBV DNA, ALT, the degree of fibrosis or inflammation, age, family history of cirrhosis or cancer, and comorbidities. Antiviral therapy with nucleos(t)ide analogues and, in selected patients, pegylated interferon, aims to suppress replication, normalise ALT, achieve seroconversion where possible, and prevent progression to cirrhosis and hepatocellular carcinoma. Because cccDNA persists, treatment is usually long-term and stopping rules are conservative.

Monitoring

Patients not yet treated still need regular follow-up — ALT, HBV DNA, HBsAg and HBeAg status, and assessment of fibrosis — because phase transitions occur silently. Patients on treatment are monitored for response, adherence and resistance, and those with cirrhosis or a family history of liver cancer continue with ultrasound and alpha-fetoprotein surveillance regardless of viral suppression.

Sources and further reading

One reference to a U.S. government health source (National Institutes of Health or MedlinePlus) for the medical background of this guide. It is context, not a substitute for advice from your treating doctor.

General information for international patients, not medical advice or a diagnosis. Read the medical disclaimer.